Future studies should encompass oral administration, detailed PK/PD characterization, chronic T2DM and complication models, direct functional assays on transporters and combination regimens with established antidiabetic drugs, in order to more precisely define the role of LASSBio-1986 in the evolving therapeutic landscape shaped by SGLT2 inhibitors and other multitarget agents [4,5,9,10,11,12,19,20,21,22,25,26,27,28,29,30,31]. Here, SLC5A2 is linked to type 2 diabetes mellitus.